- Therapeutic agent pcnsl (by machine translation)
-
The present invention provides a malignant lymphoma therapeutic or preventive agent that comprises as the active ingredient a compound represented by general formula [1] as defined by (I) or (II), or a pharmaceutically acceptable salt thereof. [1] (I) X is CH or N; R1 is a halogen; R2 is a halogen, H, a cyano, a group represented by general formula [9], [9] an optionally substituted heteroaryl, or the like; R3 is H or a hydroxyl; R4 is H or an alkyl; and R5 is H or an alkyl. (II) X is -CRA, RA is -CORB, RB is an optionally substituted amino, alkoxy, or saturated cyclic amino group; R1 is a halogen; R2 is H; R3is H or a hydroxy; R4 is H or an alkyl; and R5 is H or an alkyl.
- -
-
Paragraph 0147
(2016/10/09)
-
- DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
-
Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
- -
-
Page/Page column 52-53
(2010/12/29)
-